Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass
Under terms of the agreement, Amgen will pay up to $1 billion: $425 million in cash at closing and up to $575 million in additional payments upon the achievement of certain regulatory and sales milestones.